News >

Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Approved in Europe for Nonsquamous NSCLC

Jason M. Broderick @jasoncology
Published: Friday, Sep 06, 2019

Sandra Horning, MD, chief medical officer and head of Global Product Development, Roche

Sandra Horning, MD

The European Commission has approved atezolizumab (Tecentriq) for use in combination with carboplatin and nab-paclitaxel (Abraxane) for the first-line treatment of adult patients with advanced, nonsquamous non–small cell lung cancer (NSCLC) who do not have EGFR or ALK molecular aberrations, according to Roche (Genentech) the developer of the PD-L1 inhibitor.1

In the United States, the FDA is scheduled to make an approval decision on this atezolizumab regimen by December 2, 2019.

References

  1. European Commission approves Roche's new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer. Roche. Published September 6, 2019. Access September 6, 2019. https://bit.ly/2kmVbVV.
  2. Cappuzzo F, McCleod M, Hussein M, et al. IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann Oncol. 2018;29(supp 8, abstr LBA53). doi: 10.1093/annonc/mdy424.065.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x